Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Four dead, 65 sick in New York City Legionnaires' disease outbreak
1 Aug 2015 at 1:49pm
By Katie Reilly NEW YORK (Reuters) - A deadly outbreak of Legionnaires' disease, a severe type of pneumonia, has now killed four people and sickened 65 in the Bronx section of New York City since July 10, New York City health officials said on Saturday. This wave of Legionnaires', which officials have called unusual, is now more than five times the number of cases recorded in the last outbreak, in which 12 people in the Bronx fell ill in December 2014. The disease is caused by Legionella, a bacteria found in certain plumbing systems, including hot tubs, humidifiers, cooling towers and hot water tanks.
Fetal tissue research declining, still important
1 Aug 2015 at 11:31am
By Julie Steenhuysen CHICAGO (Reuters) - A political battle over the use of fetal tissue in medical research has been reinvigorated by the release of undercover videos targeting Planned Parenthood officials. Newer, less-controversial technologies, including the ?reprogramming? of adult skin cells to create specific types of stem cells, have rendered fetal tissue less central - though still important - to medical research, they said. Dr. Robert Lanza, chief scientific officer of Advanced Cell Technology, said that much of tissue needed for research "can now be generated in the laboratory." At Massachusetts General Hospital in Boston, for instance, only about 10 out of 8,000 active research protocols involve fetal tissue, according to an official at the Harvard-affiliated hospital who asked to remain anonymous.
NYC Doctor, Who Survived Ebola, Says Experimental Vaccine Could Be 'A Way For...
1 Aug 2015 at 6:44am
A New York City doctor, who made headlines after he was diagnosed with Ebola, said he hoped an experimental vaccine could be ?a way forward? for a region decimated by the deadly virus. Craig Spencer, an emergency room physician at NewYork-Presbyterian/Columbia University Medical Center, made headlines last year when he contracted Ebola after treating patients for the disease in Guinea. After his treatment Spencer returned to Guinea to treat patients and he got to see firsthand how the vaccine trial affected patients and health care workers.
Kenya mulls granting refuge to chimps from Ebola-hit Liberia
1 Aug 2015 at 2:34am
By Edith Honan NAIROBI (Reuters) - Kenyan officials said on Friday they were considering conservationists' appeals to give two baby chimpanzees, rescued from possible traffickers in ebola-hit Liberia, sanctuary in a Kenyan reserve but public health fears were holding up transfer. Conservationists believe the animals had been victims of trafficking that sent baby chimps from West and Central Africa to Chinese zoos and private estates in the Middle East, where they can fetch as much as $25,000. Ebola has killed more than 11,200 people in West Africa since it broke out in December 2013.
Breakthrough in quest for Ebola vaccine
1 Aug 2015 at 12:31am
An Ebola test vaccine provided blanket protection in a field trial in Guinea, researchers said, possibly heralding "the beginning of the end" for the devastating West African outbreak that has killed thousands. The serum was 100 percent effective after a week in more than 7,600 people inoculated, according to results published in The Lancet medical journal and hailed as "extremely promising" by World Health Organization (WHO) chief Margaret Chan. The world was "on the verge of an effective Ebola vaccine," the UN's health agency said in a statement.
Virginia pursuing school policing reforms following Center probe
1 Aug 2015 at 12:00am
Virginia pursuing changes in wake of Center probe
Rio pledges cleaner waters for Olympics next year
31 Jul 2015 at 10:10pm
By Karolos Grohmann KUALA LUMPUR (Reuters) - Efforts to improve the water quality for the Rio de Janeiro 2016 Olympics are ongoing, Games organizers said on Saturday, adding the welfare of the athletes was a top priority after reports of severe pollution off the shores of the Brazilian metropolis. Privately commissioned tests of the water quality, where rowers, sailors and open water swimmers will be competing, revealed this week a high level of disease-causing viruses. The waters along Rio's Atlantic coast, including Guanabara Bay where sailing events will be held, have been polluted for years and successive governments have spent hundreds of millions of dollars on supposed clean-ups to little effect.
India court concludes hearing Maggi noodles case
31 Jul 2015 at 10:07pm
An Indian court has concluded hearing a case filed by Nestle India challenging a local regulator's report that Maggi instant noodles contained excess lead, a lawyer for the company said. The Bombay High Court will give a judgment at a later date, Rajesh Batra said in a statement late on Friday. Nestle has been at the center of India's worst food scare in a decade after a regulator in the northern state of Uttar Pradesh in May said it found excess lead in a sample of the firm's popular Maggi noodles.
Olympics-Rio pledges cleaner waters for Olympics next year
31 Jul 2015 at 9:37pm
By Karolos Grohmann KUALA LUMPUR, Aug 1 (Reuters) - Efforts to improve the water quality for the Rio de Janeiro 2016 Olympics are ongoing, Games organisers said on Saturday, adding the welfare of the athletes was a top priority after reports of severe pollution off the shores of the Brazilian metropolis. Privately commissioned tests of the water quality, where rowers, sailors and open water swimmers will be competing, revealed this week a high level of disease-causing viruses. "The bay is the most iconic part of the Rio 2016 legacy," Games communications chief Mario Andrada told the International Olympics Committee in a progress presentation just over a year before the Games start on Aug 5, 2016.
1st legal medical pot sold in Nevada 15 years after approval
31 Jul 2015 at 7:44pm
SPARKS, Nev. (AP) ? Fifteen years after Nevadans voted to legalize it, medical marijuana was sold legally in the state for the first time Friday at a dispensary in a strip mall about 5 miles east of downtown Reno.
Record Heat: How the Body Reacts to Soaring Temperatures
31 Jul 2015 at 5:15pm
Officials in both Iran and Iraq declared a mandatory holiday this month after temperatures soared far into the triple digits. In Iraq, temperatures reached a sweltering 126 degrees and officials declared a mandatory holiday to try and protect people from succumbing to the heat. In Iran, the country faced possible record-breaking temperatures and high humidity that will leave residents feeling they are in temperatures as high as 151.2 degrees Fahrenheit, or 66.2 degrees Celsius.
Clinton releases tax, health records on busy Friday
31 Jul 2015 at 4:59pm
WASHINGTON (AP) ? Hillary Rodham Clinton and her husband paid close to $44 million in federal taxes since 2007 and she is in "excellent physical condition" ? two facts that emerged Friday in a flood of disclosures about the Democratic presidential candidate pushed out by her campaign on a busy summer day.
Anti-abortion group is sued over video releases
31 Jul 2015 at 4:44pm
In a complaint filed in San Francisco federal court, the National Abortion Federation, a nonprofit representing abortion providers, accused the Center for Medical Progress and its founder, David Daleiden, of illegally infiltrating and recording its private meetings. U.S. District Judge William Orrick late Friday issued a temporary restraining order blocking the defendants from releasing videos and audio recordings containing NAF member names and addresses, and dates and locations of future meetings, pending a hearing on Monday. Orrick said the NAF would likely prevail on the merits of its lawsuit, and said it could face "harassment, intimidation, violence, invasion of privacy, and injury to reputation" absent a halt.
Judge blocks release of recordings by anti-abortion group
31 Jul 2015 at 4:06pm
SAN FRANCISCO (AP) ? A federal judge has blocked the release of any recordings made at meetings of abortion providers by an anti-abortion group that previously revealed secretly recorded videos of a Planned Parenthood leader.
Chimps in New York animal rights lawsuit to be retired from lab
31 Jul 2015 at 3:57pm
By Katie Reilly NEW YORK (Reuters) - The chimpanzees at the center of a New York State Supreme Court case over the legal rights of animals will no longer be used for research, officials at the State University of New York at Stony Brook said on Friday. The retirement of the chimps, named Hercules and Leo, follows a failed bid by an animal rights group in state court to get the primates released on legal grounds. The Nonhuman Rights Project, which advocates for the legal rights of animals, in March sued Stony Brook, where the chimps were used for physiological research.